Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

| Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

After a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech is sharing ...

After publishing early clinical results of its ultrasound-activated brain tumor therapy this year, Alpheus Medical has raised ...

Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline.

After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...